• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences appoints Vincent Brichard as vice-president Immuno-Oncology

January 8, 2015 By Celyad

Mont-Saint-Guibert, Belgium –Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3 BioSciences. 

Vincent Brichard is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. In 2002, he joined GlaxoSmithKline Biologicals, where he led the Cancer Vaccines Business Unit. Until recently, Vincent was the Senior Vice President of the Immunotherapeutics Business Unit, and member of the Vaccines Executive team at GSK Biologicals

Vincent Brichard will give all support required to build another asset of the Company, by driving, from preclinical towards commercialisation, the development of the products of the immunooncology platform.

Vincent Brichard will continue to hold other non-executive positions with other companies, and will continue to bring his expertise to those and other companies in the future.

Dr. Vincent Brichard, Vice President Immuno-oncology at Cardio3 BioSciences, said: “I am pleased to have the opportunity to contribute to the development of Cardio3 BioSciences in the very exciting field of Immuno-Oncology. With the newly acquired CAR T-cells targets, I am confident that Cardio3 BioSciences will have the opportunity to become a major player in this promising field in the near future.”

Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented: “We are extremely pleased to be able to count on Vincent Brichard’s expertise to develop our new immuno-oncology franchise. His tremendous experience and closed ties with the pharmaceutical industry will be instrumental to lead our new CAR T-cells technology platform to clinical success in the coming months, and generate significant value creation opportunities to our Company.”

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy